Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab...

Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab...

Recorded @ ASCO 2019 Press Briefing, Chicago, June 1, 2019. More info @ http://oncoletter.ch